Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-15-002184
Filing Date
2015-11-03
Accepted
2015-11-03 17:00:50
Documents
10
Period of Report
2015-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nvls-20150930x10q.htm 10-Q 1529660
2 EX-31.1 nvls-20150930ex3115a8c84.htm EX-31.1 17602
3 EX-31.2 nvls-20150930ex312e2cda8.htm EX-31.2 17608
4 EX-32.1 nvls-20150930ex321cb010f.htm EX-32.1 9159
  Complete submission text file 0001558370-15-002184.txt   3704499

Data Files

Seq Description Document Type Size
5 EX-101.INS nvls-20150930.xml EX-101.INS 526420
6 EX-101.SCH nvls-20150930.xsd EX-101.SCH 20468
7 EX-101.CAL nvls-20150930_cal.xml EX-101.CAL 30957
8 EX-101.DEF nvls-20150930_def.xml EX-101.DEF 62792
9 EX-101.LAB nvls-20150930_lab.xml EX-101.LAB 221763
10 EX-101.PRE nvls-20150930_pre.xml EX-101.PRE 156867
Mailing Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301
Business Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301 720-945-7700
Nivalis Therapeutics, Inc. (Filer) CIK: 0001626199 (see all company filings)

EIN.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37449 | Film No.: 151194442
SIC: 2834 Pharmaceutical Preparations